Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Colorectal Cancer Stage IV Clinical Trial

— VIVA  

Official title:

Study of Adjuvant Durvalumab (MEDI4736) Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05382741
• Other study ID #: VIVA TRIAL
• Status: Recruiting
• Phase: Phase 2
• Start date: March 2, 2022
• Est. completion date: March 2, 2024

Study information

• Verified date: May 2023
• Source: Ospedale Policlinico San Martino
• Contact: Alberto Sobrero, MD
• Phone: +39 010 555 4386
• Email: alberto.sobrero[@]hsanmartino.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state. The NED state can be achieved in any line of treatment and it is defined as: 1. R0 resection for surgery, 2. the complete ablation defect covering the lesion on CT scan for radiofrequency, 3. the erogation of ≥ 60 Gy for stereotactic radiotherapy, 4. complete response to antineoplastic treatments on CT scan. In all these cases CEA and CA 19.9 must be within normal limits at the time of randomization. Participants in this study will receive: Experimental arm: Regorafenib 90 mg d1-21 every 28 days plus Durvalumab 1500 mg every 28 days for 1 year Control arm: Observation (crossover to Experimental arm is allowed in case of relapse) Tumor assessment will be performed every 12 weeks.

Description:

The safety run-in phase is planned for the first 4 patients randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if < 2 patients report serious adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 182
• Est. completion date: March 2, 2024
• Est. primary completion date: March 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years; ECOG PS 0-1;

2. Body weight >30 kg;

3. Histologically confirmed diagnosis of colorectal adenocarcinoma;

4. Patients must be in NED after completion of any treatments for stage IV CRC, including resections, RFA; RT with or without neoadjuvant/adjuvant therapies or CR after chemotherapy;

5. Patients must be randomized within 10 weeks since the achievement of the NED state. Those who have also received adjuvant therapy following the locoregional treatment are still eligible, provided they are randomized within 4 weeks since the last chemotherapy cycle;

6. NED state ascertained by means of CT scan and/or PET scan and/or MRI scan;

7. Life expectancy of at least 12 weeks;

8. CEA within normal limits;

9. No residual toxicity from previous chemotherapy;

10. Adequate organ function;

Exclusion criteria:

1. MSI/dMMR patients;

2. Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia and vitiligo;

3. Active or prior documented autoimmune or inflammatory disorders;

4. Relevant concomitant comorbidities;

Related Conditions & MeSH terms

• Colorectal Cancer Stage IV
• Colorectal Neoplasms

Intervention

Drug:
• Durvalumab Injection for intravenous use 500 mg vial solution for infusion
MEDI4736
• Regorafenib 30 mg capsules
BAY73-4506

Locations

Country	Name	City	State
Italy	IRCCS Ospedale Policlinico San Martino	Genova	Liguria

Sponsors (4)

Lead Sponsor	Collaborator
Ospedale Policlinico San Martino	Associazione Italiana per la Ricerca sul Cancro, Bayer, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Free Survival	Disease free survival, defined as the time from the date of randomization to the earliest documented disease relapse (local or distant), death due to any cause or two consecutive increases of CEA above upper limit (time gap no longer than 30 days).	approximately 48 months
Secondary	18 months - Disease Free Survival	Disease free survival, defined as the time from the date of randomization to the earliest documented disease relapse (local or distant), death due to any cause or two consecutive increases of CEA above upper limit (time gap no longer than 30 days).	approximately 48 months
Secondary	Overall Survival	Overall survival, defined as the time from the date of randomization to death due to any cause	approximately 48 months
Secondary	Incidence of adverse events	An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.; Toxicity/adverse events are classified according to NCI CTCAE version 5.0.	approximately 48 months